Design, Synthesis and Biological Evaluation of Xanthone Derivatives for Possible Treatment of Alzheimer's Disease Based on Multi-Target Strategy.

Chemistry & Biodiversity
Aihong YangRui Shen

Abstract

Four xanthone derivatives were synthesized and evaluated as acetylcholinesterase inhibitors (AChEIs) with metal chelating ability and antioxidant ability against Alzheimer's disease (AD). Most of them exhibited potential acetylcholinesterase (AChE), butylcholinesterase (BuChE) inhibitory, antioxidant and metal chelating properties. Among them, 1-hydroxy-3-[2-(pyrrolidin-1-yl)ethoxy]-9H-xanthen-9-one had the highest ability to inhibit AChE and displayed high selectivity towards AChE (IC50 =2.403±0.002 μM for AChE and IC50 =31.221±0.002 μM for BuChE), and it was also a good antioxidant (IC50 =2.662±0.003 μM). Enzyme kinetic studies showed that this compound was a mixed-type inhibitor, which could interact simultaneously with the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE. Interestingly, its copper complex showed more significant inhibitory activity for AChE (IC50 =0.934±0.002 μM) and antioxidant activity (IC50 =1.064±0.003 μM). Molecular dockings were carried out for the four xanthone derivatives in order to further investigate the binding modes. Finally, the blood-brain barrier (BBB) penetration prediction indicated that all compounds might penetrate BBB. These results suggested that 1-hydroxy-3-[...Continue Reading

References

Jul 30, 1982·Science·R T BartusA S Lippa
Feb 24, 2001·Annals of the New York Academy of Sciences·M P CuajungcoA I Bush
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Nov 16, 2006·Current Pharmaceutical Design·Ana Castro, Ana Martinez
Aug 28, 2007·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Guang-Rong ZhaoLi-Bin Zhao
May 9, 2008·Journal of Asian Natural Products Research·Gwendoline Cheng Lian EeMawardi Rahmani
Aug 17, 2010·Bioorganic & Medicinal Chemistry·Clementina M M SantosEduarda Fernandes
Sep 20, 2011·European Journal of Medicinal Chemistry·Michela RosiniCarlo Melchiorre
Mar 29, 2014·Chemical Society Reviews·David J HaynePaul S Donnelly
Aug 31, 2014·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·K Y KhawV Murugaiyah
Sep 17, 2014·Natural Product Reports·Tim WezemanKye-Simeon Masters
Apr 12, 2016·Chemico-biological Interactions·Natalia N Nalivaeva, Anthony J Turner
Oct 12, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jingya RuanTao Wang
Oct 29, 2017·Redox Biology·C CheignonF Collin
Mar 23, 2018·Journal of Alzheimer's Disease : JAD·Paul A Adlard, Ashley I Bush
Sep 8, 2018·Current Medicinal Chemistry·Leide Caroline Dos Santos PicancoLorane Izabel da Silva Hage-Melim
Jul 16, 2019·Journal of Alzheimer's Disease : JAD·Christin NanceSarah J Banks

❮ Previous
Next ❯

Citations

Feb 20, 2021·European Journal of Pharmacology·Aihong YangRui Shen
Aug 23, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Chang LiuRui Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.